{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:15:54Z","timestamp":1790583354192,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7549","license":[{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2015,4,30]]},"DOI":"10.1038\/nature14418","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T10:35:13Z","timestamp":1429698913000},"page":"697-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":210,"title":["TP53 loss creates therapeutic vulnerability in\u00a0colorectal cancer"],"prefix":"10.1038","volume":"520","author":[{"given":"Yunhua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecil","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Rodriguez-Aguayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Lopez-Berestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pulivarthi H.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen M.","family":"Maru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Anderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongbin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"key":"BFnature14418_CR1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/humu.20495","volume":"28","author":"A Petitjean","year":"2007","unstructured":"Petitjean, A. et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28, 622\u2013629 (2007)","journal-title":"Hum. Mutat."},{"key":"BFnature14418_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nrd2656","volume":"7","author":"A Vazquez","year":"2008","unstructured":"Vazquez, A. et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nature Rev. Drug Discov. 7, 979\u2013987 (2008)","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnature14418_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrclinonc.2010.174","volume":"8","author":"CF Cheok","year":"2011","unstructured":"Cheok, C. F. et al. Translating p53 into the clinic. Nature Rev. Clin. Oncol. 8, 25\u201337 (2011)","journal-title":"Nature Rev. Clin. Oncol."},{"key":"BFnature14418_CR4","first-page":"a001222","volume":"2","author":"DP Lane","year":"2010","unstructured":"Lane, D. P., Cheok, C. F. & Lain, S. p53-based cancer therapy. Cold Spring Harb. Perspect. Biol. 2, a001222 (2010)","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"BFnature14418_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrc991","volume":"3","author":"P Ch\u00e8ne","year":"2003","unstructured":"Ch\u00e8ne, P. Inhibiting the p53\u2013MDM2 interaction: an important target for cancer therapy. Nature Rev. Cancer 3, 102\u2013109 (2003)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature14418_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade, M., Li, Y. C. & Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Rev. Cancer 13, 83\u201396 (2013)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature14418_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.semcancer.2004.04.003","volume":"14","author":"S Haupt","year":"2004","unstructured":"Haupt, S. & Haupt, Y. Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin. Cancer Biol. 14, 244\u2013252 (2004)","journal-title":"Semin. Cancer Biol."},{"key":"BFnature14418_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4161\/trns.2.3.16172","volume":"2","author":"O Bensaude","year":"2011","unstructured":"Bensaude, O. Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity? Transcription 2, 103\u2013108 (2011)","journal-title":"Transcription"},{"key":"BFnature14418_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1126\/science.170.3956.447","volume":"170","author":"TJ Lindell","year":"1970","unstructured":"Lindell, T. J. et al. Specific inhibition of nuclear RNA polymerase II by \u03b1-amanitin. Science 170, 447\u2013449 (1970)","journal-title":"Science"},{"key":"BFnature14418_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/toxsci\/kfj141","volume":"91","author":"K Letschert","year":"2006","unstructured":"Letschert, K. et al. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol. Sci. 91, 140\u2013149 (2006)","journal-title":"Toxicol. Sci."},{"key":"BFnature14418_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jnci\/djs140","volume":"104","author":"G Moldenhauer","year":"2012","unstructured":"Moldenhauer, G. et al. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J.\u00a0Natl. Cancer Inst. 104, 622\u2013634 (2012)","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"BFnature14418_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrm2858","volume":"11","author":"S Negrini","year":"2010","unstructured":"Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability\u2013an evolving hallmark of cancer. Nature Rev. Mol. Cell Biol. 11, 220\u2013228 (2010)","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnature14418_CR13","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.cell.2012.07.023","volume":"150","author":"D Nijhawan","year":"2012","unstructured":"Nijhawan, D. et al. Cancer vulnerabilities unveiled by genomic loss. Cell 150, 842\u2013854 (2012)","journal-title":"Cell"},{"key":"BFnature14418_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature11331","volume":"488","author":"FL Muller","year":"2012","unstructured":"Muller, F. L. et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337\u2013342 (2012)","journal-title":"Nature"},{"key":"BFnature14418_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014)","journal-title":"Science"},{"key":"BFnature14418_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nrc2012","volume":"6","author":"F Toledo","year":"2006","unstructured":"Toledo, F. & Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature Rev. Cancer 6, 909\u2013923 (2006)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature14418_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.1246981","volume":"343","author":"T Wang","year":"2014","unstructured":"Wang, T. et al. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80\u201384 (2014)","journal-title":"Science"},{"key":"BFnature14418_CR18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","volume":"153","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering. Cell 153, 910\u2013918 (2013)","journal-title":"Cell"},{"key":"BFnature14418_CR19","doi-asserted-by":"publisher","first-page":"12778","DOI":"10.1073\/pnas.0705317104","volume":"104","author":"FA Derheimer","year":"2007","unstructured":"Derheimer, F. A. et al. RPA and ATR link transcriptional stress to p53. Proc. Natl Acad. Sci. USA 104, 12778\u201312783 (2007)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature14418_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2012.12.021","volume":"23","author":"J Lu","year":"2013","unstructured":"Lu, J. et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23, 171\u2013185 (2013)","journal-title":"Cancer Cell"},{"key":"BFnature14418_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0076-6879(85)12019-7","volume":"112","author":"H Faulstich","year":"1985","unstructured":"Faulstich, H. & Fiume, L. Protein conjugates of fungal toxins. Methods Enzymol. 112, 225\u2013237 (1985)","journal-title":"Methods Enzymol."},{"key":"BFnature14418_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","volume":"35","author":"PT Went","year":"2004","unstructured":"Went, P. T. et al. Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 35, 122\u2013128 (2004)","journal-title":"Hum. Pathol."},{"key":"BFnature14418_CR23","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1158\/1535-7163.MCT-14-0074","volume":"13","author":"CV Pecot","year":"2014","unstructured":"Pecot, C. V. et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol. Cancer Ther. 13, 2876\u20132885 (2014)","journal-title":"Mol. Cancer Ther."},{"key":"BFnature14418_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/cgt.2010.63","volume":"18","author":"I Goldstein","year":"2011","unstructured":"Goldstein, I. et al. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 18, 2\u201311 (2011)","journal-title":"Cancer Gene Ther."},{"key":"BFnature14418_CR25","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1128\/JVI.06245-11","volume":"86","author":"Y Liu","year":"2012","unstructured":"Liu, Y. et al. Kaposi\u2019s sarcoma-associated herpesvirus-encoded microRNA miR-K12-11 attenuates transforming growth factor beta signaling through suppression of SMAD5. J. Virol. 86, 1372\u20131381 (2012)","journal-title":"J. Virol."},{"key":"BFnature14418_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013)","journal-title":"Science"},{"key":"BFnature14418_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-1-60761-753-2_15","volume":"649","author":"DY Guschin","year":"2010","unstructured":"Guschin, D. Y. et al. A rapid and general assay for monitoring endogenous gene modification. Methods Mol. Biol. 649, 247\u2013256 (2010)","journal-title":"Methods Mol. Biol."},{"key":"BFnature14418_CR28","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8, 2281\u20132308 (2013)","journal-title":"Nature Protocols"}],"updated-by":[{"DOI":"10.1038\/s41586-021-03664-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nature14418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature14418","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature14418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T19:03:57Z","timestamp":1629918237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature14418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,22]]},"references-count":28,"journal-issue":{"issue":"7549","published-print":{"date-parts":[[2015,4,30]]}},"alternative-id":["BFnature14418"],"URL":"https:\/\/doi.org\/10.1038\/nature14418","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,22]]},"assertion":[{"value":"21 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-021-03664-3","URL":"https:\/\/doi.org\/10.1038\/s41586-021-03664-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.A. and A.P. are employees of Heidelberg Pharma GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}